GDF-15 as a Possible Biomarker for Use and Dosing of Metformin in Type II Diabetes

January 30, 2017
Blog, Diabetes, Utilized Myriad RBM's Services

Novel nonglycemic biomarker for metformin

The Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial delivers more insight on biomarkers that have potential to help treat patients with dysglycemia.1 Hertzel C. Gerstein and colleagues report Growth Differentiation Factor 15 as a novel biomarker for the use and dosing of metformin, in a study published in Diabetes Care last month.

Read More

Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia

November 19, 2015
Cardiac, Diabetes, Utilized Myriad RBM's Services

An international team of researchers used Myriad RBM’s Multi-Analyte Profile (MAP) technology to identify a pattern of cardiometabolic biomarkers that appears to predict cardiovascular outcomes in patients with dysglycemia. This data, the latest publication stemming from the landmark Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, holds great promise for prognosis and treatment of patients suffering from diseases caused by abnormalities in blood glucose levels.

Read Article »

Salivary biomarkers of Type-2 Diabetes Risk in Children

June 12, 2014
Blog, Diabetes
The epidemic of obesity in America is staggering and the costs of treating the diseases associated with being overweight are increasing. The prevalence of pediatric Type-2 diabetes (T2D) is particularly troubling since there has been a marked increase in frequency. Early intervention can reverse or prevent some of the more serious side-effects of the disease but detection is critical. Here the researchers describe a study using a non-invasive collection of saliva and test for metabolic-related biomarker differences in children with T2D. https://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0098799

Myriad Announces Diabetes Collaboration with Sanofi

December 19, 2012
Blog, Diabetes, Utilized Myriad RBM's Services
As a major participant in the largest protein biomarker study of its kind, Myriad RBM will analyze more than 8,000 samples for Sanofi Aventis’ Outcome Reduction with Initial Glargine Intervention (ORIGIN) project, a pre- and early diabetes clinical study. The goal of the collaboration is to identify biomarker profiles that optimize treatment and improve care for diabetes patients. The research will be done using an expanded version of Myriad RBM’s DiscoveryMAP service and will provide quantitative measurement of nearly 300 blood-based proteins. The Population Health Research Institute (PHRI) managed the ORIGIN trial and is contributing samples and guiding data analysis to link biomarker measurements to clinical outcomes.